Key Points
- GSK insider Julie Brown bought 7 shares at GBX 1,765 each, totaling £123.55; she also purchased 7 shares in September.
- GSK shares opened at GBX 1,771, with a £70.96 billion market capitalization and a one-year trading range of GBX 1,592 to GBX 2,282.
- Analysts maintain a consensus “Hold” rating with an average price target of GBX 2,064.38, although individual targets range from GBX 1,975 to GBX 2,500.
GSK plc (LON:GSK - Get Free Report) insider Julie Brown acquired 7 shares of the business's stock in a transaction dated Friday, October 9th. The shares were acquired at an average cost of GBX 1,765 per share, with a total value of £123.55.
Julie Brown also recently made the following trade(s):
- On Wednesday, September 9th, Julie Brown acquired 7 shares of GSK stock. The stock was bought at an average price of GBX 1,803 per share, with a total value of £126.21.
GSK Trading Up 1.1%
LON:GSK opened at GBX 1,771 on Tuesday. GSK plc has a one year low of GBX 1,592 and a one year high of GBX 2,282. The business has a fifty day moving average price of GBX 1,855.63 and a 200-day moving average price of GBX 1,931.84. The firm has a market capitalization of £70.96 billion, a price-to-earnings ratio of 15.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.
GSK (LON:GSK - Get Free Report) last released its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. Sell-side analysts forecast that GSK plc will post 175.98 EPS for the current year.
Analysts Set New Price Targets
Several research firms have recently commented on GSK. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a GBX 2,000 price objective on shares of GSK in a research note on Tuesday, September 29th. Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 2,500 price objective on shares of GSK in a research report on Wednesday, July 29th. Berenberg Bank boosted their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the company a "hold" rating in a research note on Tuesday, September 15th. Finally, Royal Bank Of Canada reiterated a "sector perform" rating and set a GBX 1,975 price objective on shares of GSK in a research note on Tuesday, September 8th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of GBX 2,064.38.
Read Our Latest Report on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
